Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Pmd-PEG5-3C-Dab#1 |
Target |
Action inhibitors |
Mechanism BRAF V600E inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC52H60F3N9O12S2 |
InChIKeyVIUIPUTXCBUDAQ-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600E Mutation-Positive Melanoma | Preclinical | Canada | 10 Aug 2020 | |
BRAF V600E Mutation-Positive Melanoma | Preclinical | Canada | 10 Aug 2020 | |
BRAF V600E Mutation-Positive Melanoma | Preclinical | Canada | 10 Aug 2020 |